Advertisement Hospira introduces Imipenem-Cilastatin for Injection, IV in US - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Hospira introduces Imipenem-Cilastatin for Injection, IV in US

Hospira, a provider of injectable drugs has launched imipenem-cilastatin for injection, I.V. in the US.

Imipenem-cilastatin, a generic version of Merck’s Primaxin is a carbapenem that belongs to the beta-lactam class of antibiotics.

The medication will be made available in 250 mg and 500 mg flip-top vials.

Hospira Specialty Pharmaceuticals vice president/general manager Joshua Gordon said the company is committed to providing generic alternatives in this category of antibiotics and imipenem-cilastatin is their second carbapenem in the US.

"Hospira is committed to continuing to reduce the cost of healthcare by providing savings with first-to-market generic injectables," Gordon added.